In a phase 2 trial of 420 children aged 6 months to <9 years given six MF59-adjuvanted H5N1 vaccine formulations, HI titres ≥1:40 reached 74.6–90.0% after two doses; standard MF59 content gave higher titres without more reactogenicity.
RCTn = 420
Põder et al. Immunogenicity and safety of MF59-adjuvanted H5N1 pandemic influenza vaccine in healthy infants and children: a phase 2 randomized, observer-blind, multicenter study